US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Articles published by Prothena Corporation plc

< Previous 1 2 Next >
News headline image
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Report Second Quarter 2026 Financial Results on August 6
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Report First Quarter 2026 Financial Results on May 7
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces up to $100 Million Share Repurchase Plan
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Report Third Quarter 2025 Financial Results on November 6
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Report Second Quarter 2025 Financial Results on August 4
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces Corporate Restructuring
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Report First Quarter 2025 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
News headline image
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
< Previous 1 2 Next >